Experimental investigations on problems of the clinical use of L-asparaginase.
D000818:Animals; D000917:Antibody Formation; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001215:Asparaginase / Q000008:administration & dosage / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D004351:Drug Resistance; D004357:Drug Synergism; D004926:Escherichia coli / Q000201:enzymology*; D007114:Immunization; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007942:Leukemia, Experimental / Q000188:drug therapy* / Q000276:immunology; D008558:Melphalan / Q000627:therapeutic use; D051379:Mice; D008815:Mice, Inbred Strains; D009362:Neoplasm Metastasis; D009368:Neoplasm Transplantation; D011033:Podophyllin / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D003561:Cytarabine; D003609:Dactinomycin; D011344:Procarbazine; D014750:Vincristine; D011033:Podophyllin; D001215:Asparaginase; D008558:Melphalan